Long Term Use of Estrogen-Progestin Increased The Incidence of Breast Cancer

Articles reviewed with valid evidence agree that prolonged use of estrogen - progesterone increases the incidence of breast cancer. There are some differences in starting ET. A component of the WHI study suggests that the incidence of breast cancer may decrease in women taking estrogen without antagonism (Beckmann, 2014). Advantages of ET - Risk ratio is beneficial for women close to menopause ET (NAMS, 2012). In addition, this data supports the use of early ET to reduce the risk of menopausal disorders such as osteoporosis, vasomotor symptoms, vaginal dryness and overactive bladder (NAMS, 2012).

Women who take estrogen alone alone in patients who have undergone hysterectomy have a lower risk of breast cancer than women taking progesterone and estrogen. In a 2006 JAMA article, researchers at the Women's Health Initiative found that after about seven years of treatment with estrogen, the risk of breast cancer does not appear to increase. There are still many unknowns. Currently, many women are taking lower doses of hormones than used in WHI trials. Hormones are not only provided by pills but also in other forms such as skin patches. We still do not know whether these lower concentrations and different forms will reduce the risk.

Hormonal imbalance is an important factor in promoting breast cancer. Hormones that promote breast cancer are high levels of estrogen and progesterone (Davies 29). In a 1995 study, women with high levels of estrogen or progesterone were found to have a high incidence of breast cancer (Glazer 559). Lesbians and monasteries have the highest risk of breast cancer. The reason for this is that they usually do not have children at all and estrogen levels remain high for a lifetime (Davis 31)

A major problem surrounding HRT and ERT is the effect of estrogen on breast cancer. Researchers believe that the longer you are exposed to natural estrogens throughout your life, the greater the risk of developing breast cancer. However, it has not been confirmed that estrogens administered at menopause have the same effect. Many of the previous studies have differed due to the large differences in the dose, timing and type of estrogen studied. A recent analysis of previous studies suggests that short-term (<10 years) low-dose estrogens do not increase the risk of breast cancer. If you use a high dose (over 10 years) for a long period of time, the risk may increase significantly. There is still room for discussion. Researchers believe that long-term use may increase the risk of breast cancer by 30%. However, in order to reach some agreement, we need to monitor more women for a long time.